GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response
Authors:
- Carlo WilkeCWCarlo Wilke
- Andreas TraschützATAndreas Traschütz
- Benjamin BenderBBBenjamin Bender
- Henry HouldenHHHenry Houlden
- RFC1 study group Stephan ZüchnerRZRFC1 study group Stephan Züchner
- 11 May 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (10) , 4144-4157
Abstract
Ataxia due to an autosomal dominant intronic GAA repeat expansion in FGF14 (GAA-FGF14 ataxia, Spinocerebellar ataxia 27B [SCA27B]) has recently been identified as one of the most common genetic late-onset ataxias. We here aimed to characterise its phenotypic profile, natural history progression, and 4-aminopyridine (4-AP) treatment response. We conducted a multi-modal cohort study of 50 GAA-FGF14 patients, comprising in-depth phenotyping, cross-sectional and longitudinal progression data (up to 7 years), MRI findings, serum neurofilament light (sNfL) levels, neuropathology, and 4-AP treatment response data, including a series of n-of-1 treatment studies. GAA-FGF14 ataxia consistently presented as late-onset (60.0 years (53.5-68.5), median (IQR)) pancerebellar syndrome, partly combined with afferent sensory deficits (55%) and dysautonomia (28%). Dysautonomia increased with duration while cognitive impairment remained infrequent, even in advanced stages. Cross-sectional and longitudinal assessments consistently indicated mild progression of ataxia (0.29 SARA points/year), not exceeding a moderate disease severity even in advanced stages (max. SARA score: 18 points). Functional impairment increased relatively slowly (unilateral mobility aids after 8 years in 50% of patients). Corresponding to slow progression and low extra-cerebellar involvement, sNfL was not increased relative to controls. Concurrent second diseases (including progressive supranuclear palsy neuropathology) represented major individual aggravators of disease severity, constituting important caveats for planning future GAA-FGF14 trials. A treatment response to 4-AP with relevance for everyday living was reported by 86% of treated patients. A series of three prospective n-of-1 treatment experiences with on/off design showed marked reduction in daily symptomatic time and symptom severity on 4-AP. Our study characterises the phenotypic profile, natural history progression, and 4-AP treatment response of GAA-FGF14 ataxia. It paves the way towards large-scale natural history studies and 4-AP treatment trials in this newly discovered, possibly most frequent, and treatable late-onset ataxia.Keywords
Funding Information
- Else Kröner-Fresenius-Stiftung
This publication has 29 references indexed in Scilit:
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Experience in a short-term trial with 4-Aminopyridine in cerebellar ataxiaJournal of Neurology, 2013
- Inventory of Non-Ataxia Signs (INAS): Validation of a New Clinical Assessment InstrumentThe Cerebellum, 2012
- FGF14 N-terminal splice variants differentially modulate Nav1.2 and Nav1.6-encoded sodium channelsMolecular and Cellular Neuroscience, 2009
- Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathiesActa Neuropathologica, 2009
- FGF14 regulates the intrinsic excitability of cerebellar Purkinje neuronsNeurobiology of Disease, 2009
- Second consensus statement on the diagnosis of multiple system atrophyNeurology, 2008
- Scale for the assessment and rating of ataxiaNeurology, 2006
- Fibroblast growth factor 14 is an intracellular modulator of voltage‐gated sodium channelsThe Journal of Physiology, 2005
- Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scaleNeurology, 2005